Figure 2.
Figure 2. Ibrutinib therapy is associated with a reduction in PD1 expression on the surface of CD3+ T cells.

Ibrutinib therapy is associated with a reduction in PD1 expression on the surface of CD3+ T cells.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal